Last reviewed · How we verify
NCT04934930: FLMRD
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
Phase 2 trial testing Bendamustin in Follicular Lymphoma in 40 participants. Status unknown.
1 August 2025
Quick facts
| Lead sponsor | Meir Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 29 January 2020 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 August 2025 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Bendamustin — full drug profile →
- Obinutuzumab — full drug profile →
Conditions studied
- Follicular Lymphoma — all drugs for Follicular Lymphoma →
Sponsor
Meir Medical Center
Who can join
18 and older, any sex, with Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events. Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients even after therapy, and when detected after lymphoma treatment it is referred to as minimal residual disease (MRD). MRD elimination after effective lymphoma treatment is a marker for deep response and correlates with prolonged remission. In this study we aim to omit chemotherapy after 4 cycles of treatment in patients achieving MRD elimination after 3 months of therapy, as well as complete metabolic response on positron emission computed tomography (PET-CT), hoping to preserve treatment effectiveness while reducing adverse events.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04934930
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bendamustin
Trials testing the same drug.
- NCT06136351 — A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chem · Phase 2 · recruiting
- NCT01216683 — Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide i · Phase 2 · completed
Other recruiting trials for Follicular Lymphoma
Currently open trials in the same condition.
- NCT07128641 — Odronextamab in Low Tumor Volume Advanced FL · Phase 2 · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
- NCT07126678 — Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma · NA · recruiting
- NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
Other Meir Medical Center trials
Trials by the same sponsor.
- NCT07256886 — Validation of the iCVS Model in Patients Admitted to the Intensive Care Unit · not yet recruiting
- NCT07315477 — Characteristics of Patients Intubated for Airway Protection in the Intensive Care Unit and Timing of Tracheostomy · not yet recruiting
- NCT07183410 — Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood · not yet recruiting
- NCT07256860 — Influence of Chest X-ray vs. Chest CT Scan on the Management of ICU Patients With Respiratory Failure · not yet recruiting
- NCT05784350 — Preoperative Point of Care Ultrasound Guided Fluid Optimization and Intravenous Ondansetron to Prevent General Anesthesi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04934930 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meir Medical Center
- Last refreshed: 22 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04934930.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing